| Patents for A61K 39 - Medicinal preparations containing antigens or antibodies (182,248) |
|---|
| 09/30/2004 | US20040191236 Administering antigen associated with disease, a dendritic cell binding agent specific for the antigen, and an autologous dendritic cell; immunotherapy |
| 09/30/2004 | US20040191235 Method for obtaining antigen-specific tr1 regulatory lymphocytes |
| 09/30/2004 | US20040191229 Antitumor vaccination using allogeneic tumor cells expressing alpha (1,3)-galactosyltransferase |
| 09/30/2004 | US20040191227 Induction of immunological tolerance |
| 09/30/2004 | US20040191214 Nucleoside vaccine adjuvants |
| 09/30/2004 | US20040191170 Evaluation of infections by enteric pathogens including diarrhea caused by Escherichia and are hemorrhagic |
| 09/30/2004 | CA2520629A1 Methods of promoting the differentiation of stem cells |
| 09/30/2004 | CA2519511A1 Mutant cholera holotoxin as an adjuvant and an antigen carrier protein |
| 09/30/2004 | CA2519225A1 Inactivated vibrio cholerae vaccine in tablet form |
| 09/30/2004 | CA2519084A1 Methods for inducing the differentiation of monocytes into functional dendritic cells and immunotherapeutic compositions including such dendritic cells |
| 09/30/2004 | CA2518924A1 Process for increasing rsv surface glycoprotein yields using a mutant strain of rsv |
| 09/29/2004 | EP1462521A1 Human p53 splice variant displaying differential transcriptional activity |
| 09/29/2004 | EP1462457A1 Cytotoxic protein and utilization thereof |
| 09/29/2004 | EP1462456A1 Tumor antigens |
| 09/29/2004 | EP1462114A1 Methods and means to suppress symptons of an allergic disease by inhibiting the glucocorticoid-induced tumor necrosis factor receptor (GRIT or TNFRSF18) |
| 09/29/2004 | EP1462111A1 Composition for inducing immunotolerance |
| 09/29/2004 | EP1461450A1 T-bet compositions and methods of use thereof |
| 09/29/2004 | EP1461441A1 Flavivirus vaccine delivery system |
| 09/29/2004 | EP1461428A2 Hybrid antibodies |
| 09/29/2004 | EP1461422A1 Interleukin-2 gene transferred lymphokine activated killer cells |
| 09/29/2004 | EP1461359A2 Novel anti-igf-ir antibodies and uses thereof |
| 09/29/2004 | EP1461357A2 Novel hev antigenic peptide and methods |
| 09/29/2004 | EP1461353A2 ALLOIOCOCCUS OTITIDIS OPEN READING FRAMES (ORFs) ENCODING POLYPEPTIDE ANTIGENS, IMMUNOGENIC COMPOSITIONS AND USES THEREOF |
| 09/29/2004 | EP1461351A2 Methods and reagents for diagnosis and treatment of diabetes |
| 09/29/2004 | EP1461086A2 Enzymatic cleavable reagents for specific delivery to disease sites |
| 09/29/2004 | EP1461082A2 Antibodies against carboxic anhydrase ix (ca ix) tumor antigen |
| 09/29/2004 | EP1461081A2 Anti-cd45rb antibodies for use in treating autoimmune disease and transplant rejection |
| 09/29/2004 | EP1461080A2 Purified hepatitis c virus envelope proteins for diagnostic and therapeutic use |
| 09/29/2004 | EP1461079A2 Human immunodeficiency virus envelope clycoprotein mutants and uses thereof |
| 09/29/2004 | EP1461077A2 Polyvalent immunogen |
| 09/29/2004 | EP1461074A2 Agents for enhancing the immune response |
| 09/29/2004 | EP1461073A2 Peptide agonists of prostate-specific antigen, and uses therefor |
| 09/29/2004 | EP1461054A2 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation |
| 09/29/2004 | EP1461023A2 Prospective identification and characterization of breast cancer stem cells |
| 09/29/2004 | EP1461014A2 Amphiphilic compounds and vesicles/liposomes for organ-specific drug targeting |
| 09/29/2004 | EP1461001A2 Cancer-associated epitope |
| 09/29/2004 | EP1084147B1 Process for producing immunoglobulins for intravenous administration and other immunoglobulin products |
| 09/29/2004 | EP1037664B1 Vaccines containing attenuated bacteria |
| 09/29/2004 | EP1003503B1 Therapeutic combinations comprising amlodipin and atorvastatin |
| 09/29/2004 | EP0989999B1 Antitumoral composition based on immunogenic polypeptide with modified cell location |
| 09/29/2004 | EP0975790B1 New method for isolating polysaccharides |
| 09/29/2004 | EP0956045B1 Assembly-deficient herpesvirus vaccine |
| 09/29/2004 | EP0826006B1 Transepithelial transport of molecular species |
| 09/29/2004 | EP0804158B1 Compositions and methods for eliciting ctl immunity |
| 09/29/2004 | EP0699079B1 Bioactive and/or targeted dendrimer conjugates comprising genetic materials |
| 09/29/2004 | EP0675903B1 Bone resorption assay |
| 09/29/2004 | CN1533442A Cimeric immunomodulatory compounds and methods of using the same |
| 09/29/2004 | CN1533434A Inflenza vaccine composition |
| 09/29/2004 | CN1533433A Method for virus propagation |
| 09/29/2004 | CN1533285A Adjuvant combination formulations |
| 09/29/2004 | CN1533284A Use of biologically active HIV-1 Tat, fragments or derivatives thereof for preventing or therapeutic vaccination and/or treating other diseases |
| 09/29/2004 | CN1533242A Foot and mouth disease virus vaccine |
| 09/29/2004 | CN1532281A RFecombination of carcino-emhyyonic antigen gene fragment and gene vaccine |
| 09/29/2004 | CN1531971A Treating acute damage caused local tissue necrosis by combined monoclonal antibody |
| 09/29/2004 | CN1531970A Poplar bark lipoid adjuvant and its preparing method and using method |
| 09/29/2004 | CN1168830C Construction and expression of recombinant human B cell stimulating factor (rhBLyS) expression vector, monoclonal antibody preparation and use |
| 09/29/2004 | CN1168819C Method for preservation of biological-active material |
| 09/29/2004 | CN1168741C Monoclonal antibody anti alpha; V-integrin and it use to inhibit alpha; beta; 6-integrain attachment to fibronectine |
| 09/29/2004 | CN1168740C Cell factor gene modified antigen presentation cel/tumor cell conjugate, its preparation and use |
| 09/29/2004 | CN1168503C Veterinarian virus kind biological product heat resistig freeze drying protective agent and its preparation technique |
| 09/29/2004 | CN1168502C Porcine circovirus and parvovirus vaccine |
| 09/29/2004 | CN1168501C Poly saccharide-protein combination vaccine |
| 09/29/2004 | CN1168500C Method for generating bi-RNA-virus from synthetic RNA transcripts |
| 09/29/2004 | CN1168499C Medicament for optimising mucosal viscosity and stimulating intestinal function |
| 09/28/2004 | US6797813 AK155 antibodies and binding fragments thereof |
| 09/28/2004 | US6797811 Antibodies to chemokine receptor 88C |
| 09/28/2004 | US6797704 Systemic delivery of compounds through non-invasive bladder administration |
| 09/28/2004 | US6797696 Contacting a bodily fluid with an antibody which binds to an human aspartyl (asparaginyl) beta-hydroxylase (haah) polypeptide to form a complex and detecting the complex; treating malignant neoplasms by inhibiting haah. |
| 09/28/2004 | US6797491 Human papilloma virus treatment |
| 09/28/2004 | US6797489 PP14 fusion proteins and methods for making and using the same |
| 09/28/2004 | US6797281 Esters of I-carnitine or alkanoyl I-carnitines |
| 09/28/2004 | US6797276 Use of penetration enhancers and barrier disruption agents to enhance the transcutaneous immune response |
| 09/28/2004 | US6797275 Method of immunizing humans against Salmonella typhi using a Vi-rEPA conjugate vaccine |
| 09/28/2004 | US6797274 Compounds |
| 09/28/2004 | US6797273 Neisseria meningitidis antigen |
| 09/28/2004 | US6797272 Enhanced immunogenicity using leukotoxin chimeras |
| 09/28/2004 | US6797270 Functional derivatives of the intercellular adhesion molecule ICAM-1 in anti-viral therapy |
| 09/28/2004 | US6797268 Pharmaceutical composition useful in the treatment of peptic ulcers |
| 09/28/2004 | US6797263 Compositions and methods for achieving immune suppression |
| 09/28/2004 | US6797258 Compositions and methods for the pulmonary delivery of aerosolized macromolecules |
| 09/28/2004 | CA2162557C Conserved motif of hepatitis c virus e2/ns1 region |
| 09/23/2004 | WO2004081515A2 Purification process for bacterial cytolysin |
| 09/23/2004 | WO2004081199A2 Novel compositions and methods for the treatment of immune related disease |
| 09/23/2004 | WO2004081198A2 Methods for modulating angiogenesis with apelin compositions |
| 09/23/2004 | WO2004081190A2 Uses of il-23 agonists and antagonists; related reagents |
| 09/23/2004 | WO2004081052A1 Soluble hybrid prion proteins and their use in the diagnosis, prevention and treatment of transmissible spongiform encephalopathies |
| 09/23/2004 | WO2004081050A1 Antibody against tumor specific antigen as target |
| 09/23/2004 | WO2004081045A2 Vaccine related to modified apolipoprotein c-iii |
| 09/23/2004 | WO2004081039A1 Novel protein and its dna |
| 09/23/2004 | WO2004081037A1 Inhibitors of extracellular hsp90 |
| 09/23/2004 | WO2004081036A1 Peptidic antibiotic |
| 09/23/2004 | WO2004081028A2 Allergen peptide fragments and use thereof |
| 09/23/2004 | WO2004080490A2 Polysaccharide - staphylococcal surface adhesin carrier protein conjugates for immunization against nosocomial infections |
| 09/23/2004 | WO2004080485A1 Preventive/remedy for diseases in upper digestive tract |
| 09/23/2004 | WO2004080419A2 Humanized antibodies that recognize beta amyloid peptide |
| 09/23/2004 | WO2004080403A2 Influenza virus vaccine |
| 09/23/2004 | WO2004080400A2 Adjuvanted bovine vaccines |
| 09/23/2004 | WO2004080394A2 Stat3 antagonists and their use as vaccines against cancer |
| 09/23/2004 | WO2004080387A2 Immunogenic cd19 ligand-antigenic molecule complexes and fusion proteins |
| 09/23/2004 | WO2004080385A2 Compositions and methods for diagnosing and treating an inflammation |